Novel compounds
By developing a new compound with a specific structure, we solved the problem of existing DUB inhibitors that have not successfully entered clinical application, achieved effective inhibition of UCHL1, provided a new DUB inhibitor for cancer treatment, and reduced the cost of drugs. Risk of drug resistance and toxicity.
Patent Information
- Application Number
- CN202010193668.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2014-09-23
- Filing Date
- 2015-09-22
- Publication Date
- 2020-08-28
- Estimated Expiration
- 2035-09-22
AI Technical Summary
Existing DUB inhibitors have not yet successfully entered clinical application, and existing cancer treatment targeted drugs such as bortezomib have drug resistance and toxicity problems. New DUB inhibitors need to be developed to replace traditional targeting strategies.
Provide a new compound, the specific structure is a 5-10 membered heteroaryl ring compound with specific substituents, used to inhibit ubiquitin C-terminal hydrolase UCHL1, through the pharmaceutical form of the compound or its pharmaceutically acceptable salt form , as a DUB inhibitor for the treatment of cancer and other indications.
This compound effectively inhibits the activity of UCHL1 and has potential benefits in the treatment of cancer and other diseases, especially in reducing drug resistance and toxicity while improving therapeutic efficacy.